Arjun K Menta

Mr. Arjun K Menta

Johns Hopkins Medicine, Baltimore, Maryland, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in Trends in Cancer
Verified
Journal Article
Open access
JAJacob J. Adashek
Jacob J. Adashek
ISIshwaria M. Subbiah
Ishwaria M. Subbiah
IMIgnacio Matos
Ignacio Matos
EGElena Garralda
Elena Garralda
Arjun K MentaArjun K Menta
Arjun K Menta
VSVivek Subbiah
Vivek Subbiah
Immunotherapy (IO) has altered the therapeutic landscape for multiple cancers. There are emerging data from retrospective studies on a subset of patients who do not benefit from IO, instead experiencing rapid progression with dramatic acceleration of disease trajectory, termed 'hyperprogressive disease' (HPD). The incidence of HPD ranges from 4% to 29% from the studies reported. Biological basis and mechanisms of HPD are currently being elucidated, with one theory involving the Fc region of antibodies. Another group has shown EGFR and MDM2/MDM4 amplifications in patients with HPD. This phenomenon has polarized oncologists who debate that this could still reflect the natural history of the disease. Thus, prospective studies are urgently needed to confirm the underlying biology, predict patients who are susceptible to HPD, and determine the modality of therapy post progression.

18 November 2020 in Chemistry of Materials
Verified
Journal Article
Closed access
MDManuel N. Dominguez
Manuel N. Dominguez
MHMichael Howard
Michael Howard
JMJosef M. Maier
Josef M. Maier
SVStephanie A. Valenzuela
Stephanie A. Valenzuela
ZSZachary M. Sherman
Zachary M. Sherman
DMDelia J. Milliron
Delia J. Milliron

12 April 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
Jacob AdashekJacob Adashek
Jacob Adashek
Arjun K MentaArjun K Menta
Arjun K Menta
NRNeha K. Reddy
Neha K. Reddy
ADAakash Desai
Aakash Desai
Jason RoszikJason Roszik
Jason Roszik
VSVivek Subbiah
Vivek Subbiah
BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation—positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malignancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.

4 August 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JAJacob J. Adashek
Jacob J. Adashek
YAYadis Arroyo-Martinez
Yadis Arroyo-Martinez
Arjun K MentaArjun K Menta
Arjun K Menta
RKRazelle Kurzrock
Razelle Kurzrock
SKShumei Kato
Shumei Kato
Gastric cancer remains third leading cause of global cancer mortality and is the fifth most common type of cancer in the United States. A select number of gastric cancers harbor alterations in EGFR and/or have amplification/overexpression in the HER2; 2–35 and 9–38%, respectively. The advent of next-generation sequencing of tissue and circulating tumor DNA has allowed for the massive expansion of targeted therapeutics to be employed in many settings. There have been a handful of trials using EGFR inhibitors with modest outcomes. Using novel strategies to target multiple co-mutations as well as identifying immunoregulatory molecule expression patterns will potentially drive future trials and improve gastric cancer patient outcomes.

26 November 2024 in International Journal of Spine Surgery
Verified
Journal Article
Open access
PDF file
MBMeghana Bhimreddy
Meghana Bhimreddy
AHAndrew Hersh
Andrew Hersh
KJKelly Jiang
Kelly Jiang
CWCarly Weber-Levine
Carly Weber-Levine
ADA. Daniel Davidar
A. Daniel Davidar
NTNicholas Theodore
Nicholas Theodore
Background Robotic platforms have increased in sophistication for pedicle screw placement. Here, we review our institutional experience using ExcelsiusGPS to assess the accuracy rate of pedicle screw placement throughout the spine and characterize predictors of placement inaccuracy. Study Design Retrospective cohort study. Methods Patients from 2017 to 2022 undergoing spinal fusion surgery with ExelsiusGPS-assisted screw implantation at a single tertiary center were retrospectively identified. Patient demographics, preoperative symptoms, and operative details were collected. Postoperative computed tomography was used to classify screw placement accuracy according to the Gertzbein and Robbins scale (GRS). A stepwise multivariable ordered logistic regression analysis determined independent risk factors for clinically inaccurate screws (GRS C/D/E). Results One hundred and seventeen patients were included. Mean age was 60.6 ± 13.2 years, with 57% men, 72% white, and mean body mass index of 29.9 ± 6.4 kg/m2. Seven hundred and twenty-eight screws were placed, predominantly in the thoracic (29.5%) and lumbar (52.6%) regions. Accuracy classification indicated 670 GRS A, 31 GRS B, 22 GRS C, 4 GRS D, and 1 GRS E screws. The clinically acceptable screw placement rate (GRS A/B) was 96%. Male gender (odds ratio [OR]: 2.12, P = 0.03), revision surgery (OR: 2.43, P = 0.02), and thoracic level screw insertion (OR: 2.33, P = 0.01) were independently associated with inaccurate screw placement and explained 8.7% of the variability seen. Of the 728 screws placed, 3 required revision after postoperative imaging revealed loosening or pedicle breach. Conclusion ExcelsiusGPS-assisted screw insertion has high placement accuracy and low revision rates. Identification of predictors of inaccuracy illustrates that similar variables, such as placement in the thoracic spine and revision surgery status, apply to both freehand and robotic screw placement. Clinical Relevance Robotic spine surgery is an accurate, reliable tool that can improve patient outcomes. Factors like male gender, thoracic screw placement, and revision surgery status are associated with lower screw placement accuracy, and these factors should inform surgical decision-making when using robotic assistance. Level of Evidence 4.

25 November 2023 in World Neurosurgery
Verified
Journal Article
Closed access
TATolulope Awosika
Tolulope Awosika
ADA. Daniel Davidar
A. Daniel Davidar
AHAndrew Hersh
Andrew Hersh
Arjun K MentaArjun K Menta
Arjun K Menta
CWCarly Weber-Levine
Carly Weber-Levine
NTNicholas Theodore
Nicholas Theodore